Join the Marrow Registry

For people diagnosed with life-threatening blood cancers, like AML, leukemia, lymphoma or other diseases, a marrow transplant may be their only hope. You could save a life by joining the Be The Match® Registry.

If you are between the ages of 18 and 44, patients especially need you. Transplant doctors request younger marrow donors over 90% of the time. Medical research shows that cells from younger donors lead to the best chance for transplant success.

For those age 45 and over, we encourage you to support others in joining the registry by making a financial contribution. (If you are between the ages of 45 and 60, and you want to join the registry, you can do so online with a $100 tax-deductible payment.)

Marrow donors with diverse racial and ethnic backgrounds are especially needed as patients need donors who are a genetic match or who share their ancestry.

All you need is to:

  • Be willing to donate to any patient in need
  • Meet health guidelines
  • Agree to keep your contact information current with Be The Match
Join the Marrow Registry

Invest in Someone’s Cure

Be The Match is a nonprofit and depends on support from people like you. Your gift to Be The Match connects over 6,000 patients a year with their marrow match. Your financial contribution could be someone’s cure and will help add more potential marrow donors to the registry so transplant can become a reality for all patients.

Invest in Someone's Cure

Invest in Research to Find a Cure for AML

Please help us beat AML! Introducing a breakthrough research approach to the treatment of AML. You support means you can be a part in changing the course of this disease. Invest in research to find a cure for AML to be part of changing the landscape of AML patients.

On September 17, 2013, LLS announced a major partnership with Dr. Brian Druker, director of the Knight Cancer Institute at OHSU in Oregon, along with two major technology companies, and eventually pharmaceutical partners. The goal of collaboration: personalize treatments for Acute Myeloid Leukemia patients, such as what John Hyland lives with. There has been no new treatment options for AML within the last 30 years, as the disease is very difficult to both implement and receive. Often patients do not survive initial treatment or have lasting complications and/or relapse as a result. Druker changed the lives of CML patients completely, driving the survival rates from 30% to 92% with a simple pill taken as an outpatient. He plans to individualize treatments and do the same with AML, the most deadly form of blood cancer.

LLS and Druker have a long history together. Now we hope to do for AML what was achieved for CML. Employing multiple modern technologies and advanced genomic to change the paradigm of how AML is treated,​ the researchers will analyze samples from 900 AML patients and integrate findings from a range of technologies to identify molecular abnormalities that drive individual cases, as well as gain an understanding of the overall biological landscape of AML. Moreover, these studies will serve as a model for clinical application of precise molecular information, as a variety of drugs will be tested for their efficacy in targeting relevant abnormalities in individual patients.

Check out how Beat AML takes a novel approach to drug discovery from OHSU Video on Vimeo now!

#SwabForLife

Get the word out on social media by posting pictures of your Swab For Life.